119103-03-6

Basic information

• Product Name: 1-Azabicyclo[2.2.1]heptane-4-carboxamide(9CI)
• Synonyms: 1-Azabicyclo[2.2.1]heptane-4-carboxamide(9CI);1-azabicyclo[2.2.1]heptane-4-carboxamide
• CAS NO: 119103-03-6
• Molecular Formula: C7H12N2O
• Molecular Weight: 140.18
• Product Categories: AMIDE
• Mol File: 119103-03-6.mol

Chemical Properties

• Boiling Point: 301.9±21.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• PKA: 16.60±0.20(Predicted)
• CAS DataBase Reference: 1-Azabicyclo[2.2.1]heptane-4-carboxamide(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Azabicyclo[2.2.1]heptane-4-carboxamide(9CI)(119103-03-6)
• EPA Substance Registry System: 1-Azabicyclo[2.2.1]heptane-4-carboxamide(9CI)(119103-03-6)

Safety Data

• Hazardous Substances Data: 119103-03-6(Hazardous Substances Data)

Upstream product

• 119102-95-3 1-Aza-bicyclo[2.2.1]heptane-4-carboxylic acid; hydrochloride 
• 119102-24-8 ethyl 1-azabicyclo<2.2.1>hept-4-yl carboxylate 
• 133643-09-1 1-Aza-bicyclo[2.2.1]heptane-4-carbonyl chloride; hydrochloride 

Downstream Products

• 133366-28-6 4-cyano-1-azabicyclo<2.2.1>heptane 
• 1135935-37-3 1-azabicyclo[2.2.1]heptan-4-ylmethanamine 

Relevant articles and documents

4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF

The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.

Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl- based muscarinic receptor ligands has been studied, and the exo- azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.